Last updated: 11/07/2018 13:53:29
A Double-Blind Comparison of the Efficacy and Tolerability of Paroxetine and Imipiramine in the Treatment of Depression and Behavioural Disturbance Associated with Dementia
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Double-Blind Comparison of the Efficacy and Tolerability of Paroxetine and Imipiramine in the Treatment of Depression and Behavioural Disturbance Associated with Dementia
Trial description: A Double-Blind Comparison of the Efficacy and Tolerability of Paroxetine and Imipiramine in the Treatment of Depression and Behavioural Disturbance Associated with Dementia
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Hunter, B and Judge, R International Academy for Biomedical and Drug Research 1996 Campaign on Interface Between Psychiatry and Internal Medicine Workshop on New Therapeutic Indications of Antidepressants 3/22/1996 Brugge; Belgium
A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Hunter, B and judge, R 8th Congress of the Association of European Psychiatrists/Annual Meeting of the Royal College of Psychiatrists 7/7/1996 London; UK
A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Le Katona, C, Hunter, B, and Judge, R 10th World Congress of Psychiatry 8/23/1996 Madrid; Spain
Katona et al. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int. J. Geriatric Psychiatry 1998; 13:100-108.
Medical condition
Depressive Disorder
Product
paroxetine
Collaborators
Not applicable
Study date(s)
November 1993 to February 1995
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1995-10-02
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website